Shares in AIM-listed drug researcher Synairgen (LON:SNG) climbed by 9.52% to 208.08p (as of 11:25 BST) today after it expanded on yesterday’s announcement of clinical trial results. Patients receiving Synairgen’s treatment during a phase II trial were twice as likely to recover from COVID-19 than those on a placebo. The company is working closely with regulators to bring this to market as soon as possible.
Further updates and data analyses will be made available in due course.